Jubilant Life Sciences has been through a wonderful journey where we came across success, fruitful and long-lasting alliances, technological progress, product innovation and expansion of our presence within and beyond the country.






  • "Second Awards" under the category of Basic Inorganic, Organic Chemicals including Agro Chemicals for the outstanding export performance of the year 2015-16 by CHEMEXCIL.


  • Sustainability Award for Best Green Process in “Chemical Sector” by “FICCI Chemicals & Petrochemicals Awards, 2016”
  • Winner of two CHEMEXCIL Export Awards: Trishul Export Award 2012-13 and Gold Export Award 2011-12
  • 16th Annual Greentech Environment Award 2015 (Gold Category), conferred under “Chemicals and Pharmaceutical sector” - Gajraula plant, India


  • Jubilant Life Sciences conferred with Golden Peacock National Quality Award
  • Jubilant Life Sciences wins ASSOCHAM’s ‘Responsible Organization Excellence’ Award 2014-15


  • Jubilant Life Sciences successfully completed its Tender Offer for acquisition of minority shares of Cadista Holdings Inc. and Cadista Holdings has become a wholly-owned subsidiary of Jubilant Life Sciences Limited
  • Jubilant Life Sciences wins Excellence Awards at ‘India Pharma Awards’ 2014
  • Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014
  • Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area
  • IDRI and Jubilant Chemsys Extend Research for TB Drug Discovery
  • Jubilant Life Sciences declared winner of 'Bio Excellence Award 2014' at Bangalore India Bio 2014
  • Jubilant Biosys Announces Expansion of Drug Discovery Alliance with Janssen Pharmaceutica


  • Jubilant Life Sciences Awarded ‘Excellence Award’ by Export Promotion Bureau
  • Jubilant Life Sciences declared winner of ‘Supply Chain Excellence Awards’ at 7th Express, Logistics & Supply Chain Leadership Awards 2013
  • Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate ‘Social Responsibility’


  • Governor Washington State (USA) , Ms. Christine Gregoire visits Jubilant Life Sciences headquarters in Noida
  • Jubilant Life Sciences receives USFDA approvals for 4 Dosage Formulations in CVS and CNS therapeutic areas
  • Hon’ble Chief Minister of Gujarat , Shri Narendra Modi inaugurates Jubilant SEZ at Bharuch, Gujarat
  • Drug Discovery Collaboration with Mnemosyne Pharmaceuticals takes place


  • Jubilant Life Sciences successfully delivers early milestones in drug discovery with AstraZeneca 
  • Jubilant Life Sciences successfully delivers late stage discovery milestone in oncology programme with Endo Pharmaceuticals
  • Jubilant Life Sciences receives USFDA approval for Donepezil Hydrochloride tablets 5mg & 10 mg
  • Jubilant Life Sciences successfully delivers sets up global scale capacities for Symtet developed through in-house R&D


  • Jubilant Life Sciences demerges its Agri & Performance Polymers business to Jubilant Industries Limited (JIL)
  • Jubilant Organosys Limited changes to Jubilant Life Sciences Limited
  • Jubilant Life Sciences board approves scheme of amalgamation & demerger
  • Jubilant Life Sciences strengthens global leadership position in vitamin B3


  • Inauguration of Jubilant Kalpataru hospital at Barasat, KOLKATA,
  • Drug discovery collaboration with Lilly extends on successful delivery of prelinical candidates
  • Jubilant Life Sciences enters into drug discovery joint venture with UAB and Southern Research in the US
  • Jubilant Life Sciences intends to enter global research and drug development partnership with Duke University
  • Jubilant Life Sciences intends to work with Endo Pharmaceuticals on drug development
  • Jubilant Life Sciences  enters research collaboration with AstraZeneca research collaboration to provide AstraZeneca with new preclinical drug candidates
  • Draximage’s generic Sestamibi approved for launch in the USA, exclusive distribution agreement signed with GE Healthcare.
  • Ink Hybrid and integrated drug discovery collaboration with Orion takes place
  • Jubilant receives approval for Sestamibi in Canada
  • New partnership in drug discovery with Bioleap takes place


  • Drug Discovery partnership with Amgen Inc, USA
  • Jubilant Organosys and Lilly to Form Drug Development Joint Venture, Indian J.V. expands companies drug discovery and development collaboration
  • Jubilant  augments Clinsys Clinical Research® through acquisition of TrialStat ClinicalAnalytics®, an EDC platform
  • Jubilant acquires DRAXIS Specialty Pharmaceuticals, Inc. Canada, a contract manufacturer of sterile & non-sterile products and radiopharmaceuticals
  • Jubilant Life Sciences acquires Speciality Molecules Private Limited Engaged in the manufacturing of Fine Chemicals used by Life Science Industry including pharma, agro & cosmetic industry


  • Jubilant acquires Hollister Stier Laboratories in USA, a contract manufacturer of Sterile injectable vials and allergenic extracts


  • Jubilant acquired pharmaceutical company in USA involved in off patent drug development and supply, and owns US FDA approved manufacturing facility for solid dosage forms.
  • Jubilant acquires full service Clinical Research Organisation in USA involved in providing clinical research services, data management, biostatistics and contract staffing.
  • Jubilant acquires Target Research Associates, Inc., renamed Clinsys Inc.; a US based Clinical Research Organisation (CRO)
  • Jubilant acquires Trinity Laboratories, Inc. and its wholly owned subsidiary, Trigen Laboratories, Inc., renamed Jubilant Pharmaceuticals, Inc., a generic pharmaceutical company in USA having a US FDA approved formulations manufacturing facility
  • Jubilant enters Clinsys Clinical Research Limited business by setting up wholly owned subsidiary Jubilant Clinsys Limited


  • Jubilant enters the medicinal chemistry arena by setting up Jubilant Chemsys
  • Set up a Contract Clinical Research Organisation named Jubilant Clinsys to conduct bioavailability, bioequivalence, pharmacokinetic and phase 1 studies.
  • Jubilant sets up medicinal chemistry services business through wholly owned subsidiary Jubilant Chemsys Limited
  • Jubilant enters formulations and regulatory affairs businesses by acquiring Pharmaceuticals Services Incorporated, N.V. and PSI Supply N.V., the pharmaceutical companies in Europe.


  • Jubilant Life Sciences sets up a new state-of-the-art Research & Development Centre in Noida, near New Delhi equipped with all latest scientific instruments.


  • Jubilant Life Sciences acquires the Active Pharmaceutical Ingredients business


  • Jubilant Organosys Limited reflects changed corporate and business profile


  • Jubilant enters the Bio / chemo informatics arena by setting up Jubilant Biosys Limited
  • Jubilant enters high value-added Pyridine Derivates. Commissions Pyridine HBR and Cyano Pyridine plants.
  • Jubilant forms marketing subsidiary in the USA
  • Jubilant Life Sciences acquires acetyl plant in western India.


  • Enters high value-added Pyridine derivates. Commissions Pyridine HBR and
  • Cyano Pyridine plants.
  • Forms marketing subsidiary in the USA.
  • Acquires acetyl plant in western India.


  • Jubilant commissions first Multi-purpose fine chemicals plant. Plant for food polymer commissioned.


  • Jubilant gets an ISO 9001 certification.


  • Jubilant commissions Pyridine & Picoline plant


  • Jubilant launches its first branded product: Vamicol, an adhesive product


  • Jubilant introduces new products in Performance Chemicals segments: Poly vinyl acetate emulsion for paint, textile, paper & packaging and woodworking industry.


  • Jubilant Research & Development Centre gets recognition from Government of India.


  • Jubilant starts commercial production of Vinyl Acetate Monomer (VAM)


  • Jubilant starts initial public offering. Listing on leading stock exchanges of India


  • Incorporated as Vam Organic Chemicals Limited